Natera
Applies personalized molecular testing across reproductive health, oncology, and organ health.
$325.30
After-hours close−0.84 (−0.26%)
At close$326.14(−3.71%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 135.43%Insiders 3.10%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 143.22M · Float 136.92M · 95.6% free float
Institutions13F, as of Jun 30, 2026
881 holders · 193.95M shares · 163 new positions · 511 increased · 246 reduced · 78 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| JPMorgan Chase & Co | 12.87M | 8.98% | −521.3K | Aug 12, 2026 |
| BlackRock, Inc. | 10.91M | 7.62% | +237.3K | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 9.02M | 6.30% | −3.16M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 6.23M | 4.35% | +219.7K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 5.78M | 4.04% | +137.9K | Aug 13, 2026 |
| FMR LLC | 5.45M | 3.81% | +2.90M | Aug 13, 2026 |
| Wellington Management Group LLP | 4.04M | 2.82% | −727.9K | Aug 14, 2026 |
| State Street Corp | 3.66M | 2.55% | +238.1K | Aug 7, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| JPMorgan Chase & Co. | 9.10% | 12.83M | 13G | Jan 23, 2026 ↗ |
| T. Rowe Price Associates, Inc. | 7.80% | 10.87M | 13G | Feb 17, 2026 ↗ |
| BlackRock, Inc. | 5.60% | 7.57M | 13G | Apr 17, 2025 ↗ |
| Vanguard Capital Management | 5.08% | 7.21M | 13G | Apr 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Matthew Rabinowitz | director, officer: EXECUTIVE CHAIRMAN | 2.28M | 1.59% | Aug 7, 2026 |
| Roelof Botha | director | 1.16M | 0.81% | Jun 30, 2026 |
| Jonathan Sheena | director, other: CO-FOUNDER | 248.5K | 0.17% | Aug 14, 2026 |
| John Fesko | officer: PRESIDENT, CHIEF BUS. OFFICER | 197.3K | 0.14% | Aug 28, 2026 |
| Daniel Rabinowitz | officer: SEC. AND CHIEF LEGAL OFFICER | 170.1K | 0.12% | Aug 5, 2026 |
| Solomon Moshkevich | officer: PRESIDENT, CLINICALDIAGNOSTICS | 129.0K | 0.09% | Aug 5, 2026 |
| Steven Leonard Chapman | director, officer: CEO AND PRESIDENT | 99.9K | 0.07% | Aug 5, 2026 |
| Michael Burkes Brophy | officer: CHIEF FINANCIAL OFFICER | 51.6K | 0.04% | Aug 5, 2026 |
| James Healy | director | 46.3K | 0.03% | Apr 29, 2025 |
| Roy D. Baynes | director | 20.1K | 0.01% | Jun 30, 2026 |
4 ten-percent owners hold 4.17M shares by Form 4, outside the officers-and-directors figure above · 2 people have not refiled in the last 18 months (59.3K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 10, 2026 | John Feskoofficer: PRESIDENT, CHIEF BUS. OFFICER | Sale | 6,517 | $321.53 | 197,257 |
| Aug 10, 2026 | Jonathan Sheenadirector, other: CO-FOUNDER | Sale | 6,000 | $325.32 | 230,464 |
| Aug 7, 2026 | Jonathan Sheenadirector, other: CO-FOUNDER | Sale · 10 lots | 9,150 | $315.66 | 236,464 |
| Aug 7, 2026 | Matthew Rabinowitzdirector, officer: EXECUTIVE CHAIRMAN | Sale | 2,000 | $320.90 | 2,000 |
| Aug 3, 2026 | Jonathan Sheenadirector, other: CO-FOUNDER | Sale | 109 | $267.99 | 245,614 |
| Aug 3, 2026 | Matthew Rabinowitzdirector, officer: EXECUTIVE CHAIRMAN | Sale | 731 | $267.99 | 2,275,394 |
| Aug 3, 2026 | Daniel Rabinowitzofficer: SEC. AND CHIEF LEGAL OFFICER | Sale | 334 | $267.99 | 170,073 |
| Aug 3, 2026 | Solomon Moshkevichofficer: PRESIDENT, CLINICALDIAGNOSTICS | Sale · 7 lots | 3,410 | $265.58 | 129,019 |
| Aug 3, 2026 | John Feskoofficer: PRESIDENT, CHIEF BUS. OFFICER | Sale | 295 | $267.99 | 183,774 |
| Aug 3, 2026 | Steven Leonard Chapmandirector, officer: CEO AND PRESIDENT | Sale · 7 lots | 3,076 | $266.39 | 99,897 |
CongressHouse and Senate disclosures
Not reported.